Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AGL NASDAQ:FLGT NASDAQ:SGRY NASDAQ:WGS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLAgilon Health$112.79+7.8%$63.11$7.48▼$118.25$1.88B3.02353,611 shs417,101 shsFLGTFulgent Genetics$17.96+1.5%$16.71$13.46▼$31.04$510.06M0.94497,854 shs684,421 shsSGRYSurgery Partners$14.55+2.2%$13.90$11.41▼$24.10$1.90B1.961.53 million shs2.31 million shsWGSGeneDx$59.01+4.6%$54.54$32.21▼$170.87$1.75B1.961.05 million shs658,675 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLAgilon Health-7.23%+2.87%+21.50%+775.09%+98.60%FLGTFulgent Genetics-1.61%-6.50%+11.67%+13.90%-12.64%SGRYSurgery Partners-6.01%+0.21%+2.23%+18.09%-30.00%WGSGeneDx-6.90%+3.87%+32.16%-22.71%-11.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLAgilon Health$112.79+7.8%$63.11$7.48▼$118.25$1.88B3.02353,611 shs417,101 shsFLGTFulgent Genetics$17.96+1.5%$16.71$13.46▼$31.04$510.06M0.94497,854 shs684,421 shsSGRYSurgery Partners$14.55+2.2%$13.90$11.41▼$24.10$1.90B1.961.53 million shs2.31 million shsWGSGeneDx$59.01+4.6%$54.54$32.21▼$170.87$1.75B1.961.05 million shs658,675 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLAgilon Health-7.23%+2.87%+21.50%+775.09%+98.60%FLGTFulgent Genetics-1.61%-6.50%+11.67%+13.90%-12.64%SGRYSurgery Partners-6.01%+0.21%+2.23%+18.09%-30.00%WGSGeneDx-6.90%+3.87%+32.16%-22.71%-11.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLAgilon Health 2.20Hold$58.73-47.93% DownsideFLGTFulgent Genetics 2.20Hold$27.0050.33% UpsideSGRYSurgery Partners 2.75Moderate Buy$22.1852.45% UpsideWGSGeneDx 2.63Moderate Buy$96.4363.41% UpsideCurrent Analyst Ratings BreakdownLatest FLGT, SGRY, AGL, and WGS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026SGRYSurgery Partners Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/1/2026WGSGeneDx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026AGLAgilon Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026SGRYSurgery Partners Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/26/2026AGLAgilon Health BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$81.005/21/2026AGLAgilon Health BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.00 ➝ $95.005/15/2026WGSGeneDx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/15/2026AGLAgilon Health CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$18.75 ➝ $80.005/12/2026AGLAgilon Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026AGLAgilon Health TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$17.00 ➝ $55.005/8/2026AGLAgilon Health Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$37.50 ➝ $72.00(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLAgilon Health$5.93B0.32N/AN/A$7.64 per share14.76FLGTFulgent Genetics$322.67M1.58N/AN/A$35.80 per share0.50SGRYSurgery Partners$3.31B0.58$1.64 per share8.87$24.21 per share0.60WGSGeneDx$442.68M3.96$2.23 per share26.44$10.54 per share5.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLAgilon Health-$391.35M-$21.56N/AN/AN/A-6.09%-146.03%-24.55%8/3/2026 (Estimated)FLGTFulgent Genetics-$60.51M-$2.39N/AN/AN/A-23.04%-3.24%-2.97%7/31/2026 (Estimated)SGRYSurgery Partners-$77.90M-$0.60N/A41.574.53-2.28%1.04%0.41%8/4/2026 (Estimated)WGSGeneDx-$21.02M-$2.68N/A67.83N/A-17.58%9.15%5.21%8/4/2026 (Estimated)Latest FLGT, SGRY, AGL, and WGS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026AGLAgilon Health$1.04$1.80+$0.76$2.94$1.38 billion$1.42 billion5/5/2026Q1 2026SGRYSurgery Partners-$0.15-$0.03+$0.12-$0.28$797.69 million$810.90 million5/4/2026Q1 2026WGSGeneDx-$0.06-$0.28-$0.22-$2.16$112.46 million$102.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGLAgilon HealthN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/ASGRYSurgery PartnersN/AN/AN/AN/AN/AWGSGeneDxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLAgilon Health0.081.041.04FLGTFulgent GeneticsN/A5.315.31SGRYSurgery Partners1.171.861.69WGSGeneDx0.383.092.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLAgilon HealthN/AFLGTFulgent Genetics48.06%SGRYSurgery PartnersN/AWGSGeneDx61.72%Insider OwnershipCompanyInsider OwnershipAGLAgilon Health2.30%FLGTFulgent Genetics36.18%SGRYSurgery Partners2.00%WGSGeneDx25.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGLAgilon Health1,07616.68 million16.30 millionNot OptionableFLGTFulgent Genetics1,31528.40 million18.13 millionOptionableSGRYSurgery Partners16,000130.79 million128.17 millionOptionableWGSGeneDx1,30029.69 million22.22 millionOptionableFLGT, SGRY, AGL, and WGS HeadlinesRecent News About These CompaniesGeneDx Holdings Corp. (WGS) Class Action Lawsuit Seeks Recovery for Investors; August 3, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP1 hour ago | globenewswire.comKevin Feeley Sells 3,729 Shares of GeneDx (NASDAQ:WGS) Stock1 hour ago | marketbeat.comGeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 10,501 Shares1 hour ago | marketbeat.comGeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC2 hours ago | newsfilecorp.comNROSEN, TRUSTED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGSJune 18 at 1:16 PM | newsfilecorp.comNHagens Berman Alerts GeneDx Holdings (WGS) Investors to Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics AcquisitionJune 18 at 1:14 PM | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor HarmJune 18 at 12:00 PM | newsfilecorp.comNGeneDx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against GeneDx Holdings Corp. - WGSJune 18 at 10:54 AM | globenewswire.comWGS Shareholder Alert: GeneDx Holdings Corp. Securities Class Action Lawsuit - Investors Should Contact SueWallStJune 18 at 10:09 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GeneDx Holdings Corp. of Class Action Lawsuit and Upcoming Deadlines - WGSJune 18 at 10:00 AM | prnewswire.comWGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud LawsuitJune 17 at 8:08 PM | prnewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGSJune 17 at 6:20 PM | globenewswire.comGeneDx (NASDAQ:WGS) Shares Down 7.6% - Time to Sell?June 17 at 4:35 PM | marketbeat.comGeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCJune 17 at 3:49 PM | newsfilecorp.comNBronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor HarmJune 17 at 12:00 PM | globenewswire.comWGS DEADLINE: Levi & Korsinsky Reminds GeneDx Holdings Corp. Investors of Upcoming Securities Class Action DeadlineJune 17 at 10:15 AM | prnewswire.comGENEDX HOLDINGS CORP. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 3, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces DeadlineJune 17 at 9:42 AM | globenewswire.comFred Alger Management LLC Lowers Stock Holdings in GeneDx Holdings Corp. $WGSJune 17 at 4:32 AM | marketbeat.comROSEN, A LEADING NATIONAL FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGSJune 16 at 10:33 PM | newsfilecorp.comNGeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - HBSSJune 16 at 6:09 PM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GeneDx Holdings Corp. of Class Action Lawsuit and Upcoming Deadlines – WGSJune 16 at 4:40 PM | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Gold Is Testing Its 200-Day SMA—These 3 Mining Stocks Are the PlayBy Chris Markoch | June 15, 2026FLGT, SGRY, AGL, and WGS Company DescriptionsAgilon Health NYSE:AGL$112.79 +8.12 (+7.76%) Closing price 03:59 PM EasternExtended Trading$113.87 +1.08 (+0.96%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.Fulgent Genetics NASDAQ:FLGT$17.96 +0.26 (+1.47%) Closing price 03:59 PM EasternExtended Trading$18.00 +0.04 (+0.19%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Surgery Partners NASDAQ:SGRY$14.55 +0.32 (+2.25%) Closing price 04:00 PM EasternExtended Trading$14.56 +0.01 (+0.07%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.GeneDx NASDAQ:WGS$59.01 +2.59 (+4.59%) Closing price 04:00 PM EasternExtended Trading$58.50 -0.51 (-0.86%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
